{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T22:51:57Z","timestamp":1792277517264,"version":"4.4.0"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,4,4]],"date-time":"2025-04-04T00:00:00Z","timestamp":1743724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,4,4]],"date-time":"2025-04-04T00:00:00Z","timestamp":1743724800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Blood Cancer J."],"DOI":"10.1038\/s41408-025-01264-2","type":"journal-article","created":{"date-parts":[[2025,4,4]],"date-time":"2025-04-04T23:14:51Z","timestamp":1743808491000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Venetoclax-based treatment combinations in relapsed\/refractory multiple myeloma: practice patterns and impact of secondary cytogenetic abnormalities on outcomes"],"prefix":"10.1038","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5812-1954","authenticated-orcid":false,"given":"Abiola","family":"Bolarinwa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madhu","family":"Nagaraj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5074-8453","authenticated-orcid":false,"given":"Saurabh","family":"Zanwar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9195-1589","authenticated-orcid":false,"given":"Nadine","family":"Abdallah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1523-7388","authenticated-orcid":false,"given":"P. Leif","family":"Bergsagel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9014-9658","authenticated-orcid":false,"given":"Moritz","family":"Binder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francis","family":"Buadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9117-8696","authenticated-orcid":false,"given":"Saurabh","family":"Chhabra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5335-9533","authenticated-orcid":false,"given":"Joselle","family":"Cook","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Dingli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8780-9512","authenticated-orcid":false,"given":"Angela","family":"Dispenzieri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3853-5196","authenticated-orcid":false,"given":"Morie A.","family":"Gertz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wilson","family":"Gonsalves","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzanne","family":"Hayman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4342-364X","authenticated-orcid":false,"given":"Prashant","family":"Kapoor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8573-9434","authenticated-orcid":false,"given":"Taxiarchis","family":"Kourelis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5651-1411","authenticated-orcid":false,"given":"Nelson","family":"Leung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1556-6416","authenticated-orcid":false,"given":"Yi","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2210-2174","authenticated-orcid":false,"given":"Eli","family":"Muchtar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9314-9933","authenticated-orcid":false,"given":"Ricardo","family":"Parrondo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5950-4620","authenticated-orcid":false,"given":"Vivek","family":"Roy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taimur","family":"Sher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4640-7311","authenticated-orcid":false,"given":"Mustaqeem","family":"Siddiqui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rahma","family":"Warsame","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amie","family":"Fonder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miriam","family":"Hobbs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi Lisa","family":"Hwa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle","family":"Rogers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Udit","family":"Yadav","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. Erin","family":"Wiedmeier-Nutor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5229-4897","authenticated-orcid":false,"given":"Linda B.","family":"Baughn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5862-1833","authenticated-orcid":false,"given":"S.","family":"Vincent Rajkumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5938-3769","authenticated-orcid":false,"given":"Rafael","family":"Fonseca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8377-8111","authenticated-orcid":false,"given":"Sikander","family":"Ailawadhi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5392-9284","authenticated-orcid":false,"given":"Shaji","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,4]]},"reference":[{"key":"1264_CR1","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1038\/s41375-021-01453-5","volume":"36","author":"M Binder","year":"2022","unstructured":"Binder M, Nandakumar B, Rajkumar SV, Kapoor P, Buadi FK, Dingli D, et al. Mortality trends in multiple myeloma after the introduction of novel therapies in the United States. Leukemia. 2022;36:801\u20138.","journal-title":"Leukemia"},{"key":"1264_CR2","doi-asserted-by":"crossref","unstructured":"Kumar SK, Dispenzieri A, Lacy MQ, Gertz MA, Buadi FK, Pandey S, et al. Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients. Leukemia. 2013;25:28.","DOI":"10.1038\/leu.2013.313"},{"key":"1264_CR3","doi-asserted-by":"publisher","first-page":"2401","DOI":"10.1182\/blood-2017-06-788786","volume":"130","author":"S Kumar","year":"2017","unstructured":"Kumar S, Kaufman JL, Gasparetto C, Mikhael J, Vij R, Pegourie B, et al. Efficacy of venetoclax as targeted therapy for relapsed\/refractory t(11;14) multiple myeloma. Blood. 2017;130:2401\u20139.","journal-title":"Blood"},{"key":"1264_CR4","doi-asserted-by":"crossref","unstructured":"Mateos M-V, Moreau P, Dimopoulos MA, Hong W-J, Cooper S, Yu Y, et al. A phase III, randomized, multicenter, open-label study of venetoclax or pomalidomide in combination with dexamethasone in patients with t(11;14)-positive relapsed\/refractory multiple myeloma. J Clin Oncol. 2020;20;38.","DOI":"10.1200\/JCO.2020.38.15_suppl.TPS8554"},{"key":"1264_CR5","doi-asserted-by":"publisher","first-page":"2392","DOI":"10.1182\/blood-2017-06-788323","volume":"130","author":"P Moreau","year":"2017","unstructured":"Moreau P, Chanan-Khan A, Roberts AW, Agarwal AB, Facon T, Kumar S, et al. Promising efficacy and acceptable safety of venetoclax plus bortezomib and dexamethasone in relapsed\/refractory MM. Blood. 2017;130:2392\u2013400.","journal-title":"Blood"},{"key":"1264_CR6","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1034\/j.1600-0609.2002.01549.x","volume":"69","author":"H Spets","year":"2002","unstructured":"Spets H, Stromberg T, Georgii-Hemming P, Siljason J, Nilsson K, Jernberg-Wiklund H. Expression of the bcl-2 family of pro- and anti-apoptotic genes in multiple myeloma and normal plasma cells: regulation during interleukin-6(IL-6)-induced growth and survival. Eur J Haematol. 2002;69:76\u201389.","journal-title":"Eur J Haematol"},{"key":"1264_CR7","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1038\/nm.3076","volume":"19","author":"DR Green","year":"2013","unstructured":"Green DR, Walczak H. Apoptosis therapy: driving cancers down the road to ruin. Nat Med. 2013;19:131\u20133.","journal-title":"Nat Med"},{"key":"1264_CR8","doi-asserted-by":"crossref","unstructured":"Bazarbachi A-H, Avet-Loiseau H, Harousseau J-L, Bazarbachi A, Mohty M. Precision medicine for multiple myeloma: the case for translocation (11;14). Cancer Treat Rev. 2024;130:102823.","DOI":"10.1016\/j.ctrv.2024.102823"},{"key":"1264_CR9","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1158\/1535-7163.MCT-15-0730","volume":"15","author":"EA Punnoose","year":"2016","unstructured":"Punnoose EA, Leverson JD, Peale F, Boghaert ER, Belmont LD, Tan N, et al. Expression profile of BCL-2, BCL-XL, and MCL-1 predicts pharmacological response to the BCL-2 selective antagonist venetoclax in multiple myeloma models. Mol Cancer Ther. 2016;15:1132\u201344.","journal-title":"Mol Cancer Ther"},{"key":"1264_CR10","doi-asserted-by":"publisher","first-page":"1630","DOI":"10.1016\/S1470-2045(20)30525-8","volume":"21","author":"SK Kumar","year":"2020","unstructured":"Kumar SK, Harrison SJ, Cavo M, de la Rubia J, Popat R, Gasparetto C, et al. Venetoclax or placebo in combination with bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (BELLINI): a randomised, double-blind, multicentre, phase 3 trial. Lancet Oncol. 2020;21:1630\u201342.","journal-title":"Lancet Oncol"},{"key":"1264_CR11","doi-asserted-by":"publisher","first-page":"3748","DOI":"10.1182\/bloodadvances.2020004146","volume":"5","author":"LJ Costa","year":"2021","unstructured":"Costa LJ, Davies FE, Monohan GP, Kovacsovics T, Burwick N, Jakubowiak A, et al. Phase 2 study of venetoclax plus carfilzomib and dexamethasone in patients with relapsed\/refractory multiple myeloma. Blood Adv. 2021;5:3748\u201359.","journal-title":"Blood Adv"},{"key":"1264_CR12","doi-asserted-by":"publisher","first-page":"3602","DOI":"10.1200\/JCO.21.00443","volume":"39","author":"NJ Bahlis","year":"2021","unstructured":"Bahlis NJ, Baz R, Harrison SJ, Quach H, Ho SJ, Vangsted AJ, et al. Phase I study of venetoclax plus daratumumab and dexamethasone, with or without bortezomib, in patients with relapsed or refractory multiple myeloma with and without t(11;14). J Clin Oncol. 2021;39:3602\u201312.","journal-title":"J Clin Oncol"},{"key":"1264_CR13","doi-asserted-by":"crossref","unstructured":"Bahlis NJ, Popat R, Beksac M, Dimopoulos MA, Gatt ME, Gay F, et al. Efficacy of venetoclax-dexamethasone (VenDex) v pomalidomide-dexamethasone (PomDex) in patients (Pts) with t(11;14)-positive relapsed\/refractory multiple myeloma [t(11;14)+ RRMM]: Phase 3 CANOVA study biomarker subgroup analysis. J Clin Oncol. 2024;42.","DOI":"10.1200\/JCO.2024.42.16_suppl.7510"},{"key":"1264_CR14","unstructured":"Mateos MV BM, Dimopoulos MA, et al. Results from the randomized, open-label phase 3 CANOVA study of venetoclax-dexamethasone versus pomalidomide-dexamethasone in patients with t(11:14)-positive relapsed\/refractory multiple myeloma. https:\/\/imsannual2023.eventscribe.net\/fsPopup.asp?PresentationID=1306640&mode=presInfo. Accessed 29 September 2023."},{"key":"1264_CR15","doi-asserted-by":"crossref","unstructured":"Gagnon M-F, Midthun SM, Fangel JA, Schuh CM, Luoma IM, Pearce KE, et al. Superior detection rate of plasma cell FISH using FACS-FISH. Am J Clin Pathol. 2024;04:161.","DOI":"10.1093\/ajcp\/aqad108"},{"key":"1264_CR16","doi-asserted-by":"publisher","first-page":"e328","DOI":"10.1016\/S1470-2045(16)30206-6","volume":"17","author":"S Kumar","year":"2016","unstructured":"Kumar S, Paiva B, Anderson KC, Durie B, Landgren O, Moreau P, et al. International myeloma working group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol. 2016;17:e328\u2013e46.","journal-title":"Lancet Oncol"},{"key":"1264_CR17","doi-asserted-by":"publisher","first-page":"4691","DOI":"10.1182\/blood-2010-10-299487","volume":"117","author":"SV Rajkumar","year":"2011","unstructured":"Rajkumar SV, Harousseau JL, Durie B, Anderson KC, Dimopoulos M, Kyle R, et al. Consensus recommendations for the uniform reporting of clinical trials: report of the international myeloma workshop consensus panel 1. Blood. 2011;117:4691\u20135.","journal-title":"Blood"},{"key":"1264_CR18","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1038\/s41375-021-01471-3","volume":"36","author":"S Bal","year":"2022","unstructured":"Bal S, Malek E, Kansagra A, Usmani SZ, Vij R, Godby KN, et al. Treatment outcomes of triple class refractory multiple myeloma: a benchmark for new therapies. Leukemia. 2022;36:877\u201380.","journal-title":"Leukemia"},{"key":"1264_CR19","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1038\/s41375-021-01433-9","volume":"36","author":"S Zanwar","year":"2022","unstructured":"Zanwar S, Ho M, Kapoor P, Dispenzieri A, Lacy MQ, Gertz MA, et al. Outcomes of triple class (proteasome inhibitor, IMiDs and monoclonal antibody) refractory patients with multiple myeloma. Leukemia. 2022;36:873\u20136.","journal-title":"Leukemia"},{"key":"1264_CR20","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1002\/ajh.26083","volume":"96","author":"JL Kaufman","year":"2021","unstructured":"Kaufman JL, Gasparetto C, Schjesvold FH, Moreau P, Touzeau C, Facon T, et al. Targeting BCL-2 with venetoclax and dexamethasone in patients with relapsed\/refractory t(11;14) multiple myeloma. Am J Hematol. 2021;96:418\u201327.","journal-title":"Am J Hematol"},{"key":"1264_CR21","doi-asserted-by":"publisher","first-page":"1610276","DOI":"10.3389\/pore.2022.1610276","volume":"28","author":"VR Szita","year":"2022","unstructured":"Szita VR, Mikala G, Kozma A, Fabian J, Hardi A, Alizadeh H, et al. Targeted venetoclax therapy in t(11;14) multiple myeloma: real world data from seven hungarian centers. Pathol Oncol Res. 2022;28:1610276.","journal-title":"Pathol Oncol Res"},{"key":"1264_CR22","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-024-01081-z","volume":"14","author":"MJ Rees","year":"2024","unstructured":"Rees MJ, Mammadzadeh A, Bolarinwa A, Elhaj ME, Bohra A, Bansal R, et al. Clinical features associated with poor response and early relapse following BCMA-directed therapies in multiple myeloma. Blood Cancer J. 2024;14:122.","journal-title":"Blood Cancer J"},{"key":"1264_CR23","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1182\/blood-2019-126094","volume":"134","author":"S Harrison","year":"2019","unstructured":"Harrison S, Cavo M, De la Rubia J, Popat R, Gasparetto C, Hungria VTM, et al. T(11;14) and high expression are predictive biomarkers of response to venetoclax in combination with bortezomib and dexamethasone in patients with relapsed\/refractory multiple myeloma: biomarker analyses from the phase 3 Bellini study. Blood. 2019;134:142.","journal-title":"Blood"},{"key":"1264_CR24","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1182\/blood-2015-12-687749","volume":"128","author":"J Krejcik","year":"2016","unstructured":"Krejcik J, Casneuf T, Nijhof IS, Verbist B, Bald J, Plesner T, et al. Daratumumab depletes CD38+ immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma. Blood. 2016;128:384\u201394.","journal-title":"Blood"},{"key":"1264_CR25","doi-asserted-by":"crossref","unstructured":"Leblay N, Ahn S, Tilmont R, Poorebrahim M, Maity R, Lee H, et al. Integrated epigenetic and transcriptional single-cell analysis of t(11;14) multiple myeloma and its BCL2 dependency. Blood. 2024;04:143.","DOI":"10.1182\/blood.2023020276"},{"key":"1264_CR26","doi-asserted-by":"crossref","unstructured":"Qin J-Z, Ziffra J, Stennett L, Bodner B, Bonish BK, Chaturvedi V, et al. Proteasome inhibitors trigger NOXA-mediated apoptosis in melanoma and myeloma cells. Cancer Res. 2005;15:65.","DOI":"10.1158\/0008-5472.CAN-05-0676"}],"container-title":["Blood Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41408-025-01264-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-025-01264-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-025-01264-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,4]],"date-time":"2025-04-04T23:14:55Z","timestamp":1743808495000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41408-025-01264-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,4]]},"references-count":26,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1264"],"URL":"https:\/\/doi.org\/10.1038\/s41408-025-01264-2","relation":{},"ISSN":["2044-5385"],"issn-type":[{"value":"2044-5385","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,4]]},"assertion":[{"value":"27 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 February 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 March 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 April 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors report to conflicts of interest pertaining to the submitted work. PLB:\n                      Novartis:\n                      Research Funding;\n                      Omeros:\n                      Consultancy;\n                      Oncopeptides:\n                      Consultancy;\n                      BMS\/Celgene:\n                      Research Funding;\n                      Pfizer:\n                      Research Funding;\n                      Cellcentric:\n                      Consultancy;\n                      Janssen:\n                      Consultancy;\n                      Sanofi:\n                      Research Funding. SC:\n                      GlaxoSmithKline, Sanofi:\n                      Honoraria;\n                      Omeros:\n                      Speakers Bureau;\n                      Bristol Myers Squibb, Amgen, Janssen, Novartis, Syndax, Ionis, Sanofi, and GlaxoSmithKline:\n                      Research Funding. JC:\n                      Geron Corp:\n                      Other: Held $600 Geron Stock for 1\u2009week and sold without profit. DD:\n                      Apellis:\n                      Consultancy, Honoraria, Research Funding;\n                      K36 Therapeutics:\n                      Research Funding;\n                      Sanofi:\n                      Consultancy, Honoraria;\n                      BMS:\n                      Consultancy, Honoraria;\n                      MSD:\n                      Consultancy, Honoraria;\n                      Regeneron:\n                      Consultancy, Honoraria;\n                      Novartis:\n                      Consultancy, Honoraria;\n                      Sorrento:\n                      Consultancy, Honoraria;\n                      Genentech:\n                      Consultancy;\n                      Janssen:\n                      Consultancy, Honoraria;\n                      Alexion:\n                      Consultancy, Honoraria. AD:\n                      Alexion:\n                      Consultancy, Research Funding;\n                      Janssen:\n                      Research Funding;\n                      HaemaloiX:\n                      Research Funding;\n                      Takeda:\n                      Consultancy, Research Funding;\n                      BMS:\n                      Consultancy, Research Funding;\n                      Alnylam:\n                      Research Funding;\n                      Pfizer:\n                      Research Funding. MAG:\n                      Astra Zeneca:\n                      Honoraria;\n                      Alexion:\n                      Honoraria;\n                      Abbvie:\n                      Other: personal fees for Data Safety Monitoring board ;\n                      Prothena:\n                      Other: personal fees;\n                      Sanofi:\n                      Other: personal fees;\n                      Ionis\/Akcea:\n                      Honoraria;\n                      Alnylym:\n                      Honoraria;\n                      Johnson & Johnson:\n                      Other: personal fees;\n                      Medscape:\n                      Honoraria;\n                      Janssen:\n                      Other: personal fees;\n                      Dava Oncology:\n                      Honoraria. PK:\n                      AbbVie:\n                      Membership on an entity\u2019s Board of Directors or advisory committees, Research Funding;\n                      Kite:\n                      Membership on an entity\u2019s Board of Directors or advisory committees;\n                      Ichnos:\n                      Research Funding;\n                      Mustang Bio:\n                      Membership on an entity\u2019s Board of Directors or advisory committees;\n                      Keosys:\n                      Consultancy;\n                      Loxo Pharmaceuticals:\n                      Research Funding;\n                      Angitia Bio:\n                      Membership on an entity\u2019s Board of Directors or advisory committees;\n                      Oncopeptides:\n                      Membership on an entity\u2019s Board of Directors or advisory committees;\n                      CVS Caremark:\n                      Consultancy;\n                      Janssen:\n                      Membership on an entity\u2019s Board of Directors or advisory committees;\n                      Karyopharm:\n                      Research Funding;\n                      X4 Pharmaceuticals:\n                      Membership on an entity\u2019s Board of Directors or advisory committees;\n                      Sanofi:\n                      Membership on an entity\u2019s Board of Directors or advisory committees, Research Funding;\n                      Pharmacyclics:\n                      Membership on an entity\u2019s Board of Directors or advisory committees;\n                      BeiGene:\n                      Membership on an entity\u2019s Board of Directors or advisory committees, Research Funding;\n                      GlaxoSmithKline:\n                      Membership on an entity\u2019s Board of Directors or advisory committees, Research Funding;\n                      Bristol Myers Squibb:\n                      Research Funding;\n                      Regeneron:\n                      Research Funding;\n                      Amgen:\n                      Research Funding. TK:\n                      Novartis:\n                      Research Funding;\n                      Pfizer:\n                      Research Funding. NL:\n                      AbbVie:\n                      Current holder of\n                      stock options\n                      in a privately-held company;\n                      Checkpoint Therapeutics:\n                      Current holder of\n                      stock options\n                      in a privately-held company. YL:\n                      Pfizer:\n                      Membership on an entity\u2019s Board of Directors or advisory committees;\n                      Sanofi:\n                      Consultancy;\n                      Bristol-Myers Squibb:\n                      Consultancy, Research Funding;\n                      Caribou:\n                      Membership on an entity\u2019s Board of Directors or advisory committees;\n                      Celgene:\n                      Consultancy, Research Funding;\n                      Janssen:\n                      Consultancy, Research Funding;\n                      NexImmune:\n                      Membership on an entity\u2019s Board of Directors or advisory committees;\n                      Legend:\n                      Consultancy;\n                      Regeneron:\n                      Consultancy;\n                      Genentech:\n                      Consultancy. EM:\n                      Protego:\n                      Consultancy. RP:\n                      Bristol Myers Squibb, GSK:\n                      Research Funding;\n                      Sanofi Aventis:\n                      Honoraria;\n                      AstraZeneca:\n                      Honoraria. TS:\n                      Caelum pharma:\n                      Other;\n                      Alpha:\n                      Consultancy, Membership on an entity\u2019s Board of Directors or advisory committees;\n                      2 Pharma:\n                      Consultancy, Membership on an entity\u2019s Board of Directors or advisory committees;\n                      Prothena:\n                      Other. YLH:\n                      GSK:\n                      Honoraria;\n                      Janssen:\n                      Honoraria;\n                      Shield Therapeutics:\n                      Honoraria;\n                      MultiMedia Medical, LLC:\n                      Consultancy;\n                      Pfizer:\n                      Other: Consulting fee located to Mayo Research fund. LBB:\n                      Genentech:\n                      Consultancy. RF:\n                      AbbVie, Adaptive, Amgen, Apple, Bayer, BMS\/Celgene, Gilead, GSK, Janssen, Kite, Karyopharm, Merck Sharp & Dohme, Juno Therapeutics, Takeda, Arduro Biotech, Oncotracker, Oncopeptides, Pharmacyclics, Pfizer, RA Capital, Regeneron, Sanofi:\n                      Consultancy;\n                      Patent for FISH in MM - ~$2000\/year:\n                      Patents & Royalties: Patent for FISH in MM - ~$2000\/year;\n                      Antengene:\n                      Membership on an entity\u2019s Board of Directors or advisory committees;\n                      Celgene, Bristol Myers Squibb, Bayer, Amgen, Janssen, Kite, a Gilead company, Merck Sharp & Dohme, Juno Therapeutics, Takeda, AbbVie, Aduro Biotech, Sanofi, OncoTracker:\n                      Honoraria. SA:\n                      Xencor:\n                      Research Funding;\n                      Janssen:\n                      Consultancy, Research Funding;\n                      Amgen:\n                      Consultancy, Research Funding;\n                      Cellectar:\n                      Consultancy, Honoraria, Research Funding;\n                      Abbvie:\n                      Research Funding;\n                      Ascentage:\n                      Research Funding;\n                      GSK:\n                      Consultancy, Research Funding;\n                      Sanofi:\n                      Consultancy;\n                      BMS:\n                      Consultancy, Research Funding;\n                      Johnson and Johnson:\n                      Consultancy, Research Funding;\n                      Regeneron:\n                      Consultancy;\n                      Beigene:\n                      Consultancy;\n                      Takeda:\n                      Consultancy;\n                      Pharmacuclics:\n                      Consultancy, Research Funding;\n                      Bristol-Myers Squibb:\n                      Consultancy, Research Funding. SK:\n                      Abbvie:\n                      Membership on an entity\u2019s Board of Directors or advisory committees, Research Funding;\n                      MedImmune\/AstraZeneca:\n                      Membership on an entity\u2019s Board of Directors or advisory committees, Research Funding;\n                      Novartis:\n                      Research Funding;\n                      Celgene:\n                      Membership on an entity\u2019s Board of Directors or advisory committees, Research Funding;\n                      Adaptive:\n                      Membership on an entity\u2019s Board of Directors or advisory committees, Research Funding;\n                      Janssen:\n                      Membership on an entity\u2019s Board of Directors or advisory committees, Research Funding;\n                      Merck:\n                      Research Funding;\n                      Takeda:\n                      Membership on an entity\u2019s Board of Directors or advisory committees, Research Funding;\n                      KITE:\n                      Membership on an entity\u2019s Board of Directors or advisory committees, Research Funding;\n                      Roche:\n                      Research Funding;\n                      Sanofi:\n                      Research Funding;\n                      Oncopeptides:\n                      Other: Independent review committee participation.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"57"}}